Table 2 Primary and secondary outcomes of the PORTAL trial
| Variable | |
|---|---|
|
Primary outcomes Time to functional recovery, n (days) Patients with PDAC who start adjuvant chemotherapy at 8 weeks, n (%) | |
|
Secondary outcomes Estimated blood loss, ml Operative time, min Length of hospital stay, days 30-day morbidity, n (%) < Clavien-Dindo grade IIIa ≥ Clavien-Dindo grade IIIb 30-day mortality, n (%) 90-day mortality, n (%) 30-day readmission, n (%) Reoperation, n (%) Quality of life assessment Perioperative costs, $ In PDAC Resection margin status, n (%) Harvested lymph nodes, n Positive lymph nodes, n Recurrence, n (%) Recurrence site, n (%) Recurrence-free survival, months Overall survival, months |